Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2022 10:00 ET | Source: Elucida Oncology, Inc

Elucida Oncology to Present at Two Upcoming Conferences

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
June 01, 2022 13:30 ET | Source: Elucida Oncology, Inc

Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting

MONMOUTH JUNCTION, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today the...
May 06, 2022 11:00 ET | Source: Elucida Oncology, Inc

Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference

MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that...
April 04, 2022 10:00 ET | Source: Elucida Oncology, Inc

Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting

MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two...
March 03, 2022 13:30 ET | Source: Elucida Oncology, Inc

Elucida Oncology to Present at Two Upcoming Scientific Conferences

MONMOUTH JUNCTION, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Dr....
January 05, 2022 08:02 ET | Source: Elucida Oncology, Inc

Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones

Enrolling third dose level in Phase 1/2 dose escalation study of ELU001, our lead clinical program targeting solid tumors overexpressing folate receptor alpha (FRα) Interim Phase 1 data for ELU001 in...
January 05, 2022 08:00 ET | Source: Elucida Oncology, Inc

Elucida Oncology to Present at Two Upcoming Investor Conferences

MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno...
December 15, 2021 15:50 ET | Source: Elucida Oncology, Inc

Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference

MONMOUTH JUNCTION, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
November 22, 2021 07:30 ET | Source: Elucida Oncology, Inc

Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the...
September 17, 2021 10:15 ET | Source: Elucida Oncology, Inc

Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)

MONMOUTH JUNCTION, N.J., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that it has completed...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right